Surgical Treatment of Refractory Open Angle Glaucoma

Open Angle Glaucoma Clinical Trial

Official title:

Surgical Treatment of Refractory Open Angle Glaucoma - A Prospective, Open-Label, Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01212861
• Other study ID #: 060410
• Status: Completed
• Phase: N/A
• First received: September 29, 2010
• Last updated: September 11, 2012
• Start date: August 2010
• Est. completion date: May 2012

Study information

• Verified date: September 2012
• Source: iScience Interventional Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the safety, efficacy, and performance of the Suprachoroidal Dissection Instrument in creating a fistula between Schlemm's canal and the suprachoroidal space in refractory, open angle glaucoma subjects.

Description:

The Suprachoroidal Dissection Instrument (SDI) is a manually operated surgical instrument designed for use within Schlemm's canal. The instrument can access Schlemm's canal through a small ab-externo dissection, allowing use in eyes with scarring due to previous surgery or trauma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 4
• Est. completion date: May 2012
• Est. primary completion date: May 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Available for up to 3 years follow-up.

• Diagnosed with primary open-angle, pseudoexfoliative, or pigmentary glaucoma or more than one glaucoma diagnosis of these types.

• Subject scheduled to undergo glaucoma surgery with the Suprachoroidal Dissection Instrument involving creation of fistula between Schlemm's canal and the suprachoroidal space without combined cataract surgery.

• Subject has failed at least one incisional glaucoma surgery (trabeculectomy, tube shunt, deep sclerectomy, viscocanalostomy, canaloplasty) or angle surgery (Trabectome) OR Is not a candidate for conventional glaucoma surgery due to reasons such as the presence of scleral buckle or compromised conjunctiva.

• Subject has IOP = 16 mm Hg on maximally tolerated medications within the six week (-42 days) period prior to surgery.

• Visual field defect defined as mean deviation (MD) score worse than or equal to -10 dB on the Swedish Interactive Threshold Algorithm [SITA] Standard 24-2 Humphrey Analysis during the 6 month period prior to surgery. OR Subject has vertical cup-to-disk ratio = 0.75 during the 6 month period prior to surgery.

Exclusion Criteria:

• Significant lens opacities or patient is candidate for cataract surgery during the duration of the study.

• The patient had developmental glaucoma or a secondary glaucoma including steroid-induced, uveitic, or neovascular glaucoma (with the exception of pigmentary and pseudoexfoliative glaucoma).

• The patient has narrow angle component possibly associated with glaucoma in the operative eye.

• The subject has angle recession in the operative eye.

• Significant ocular disease other than glaucoma affecting the assessment of visual function.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Glaucoma
• Glaucoma, Open-Angle
• Open Angle Glaucoma

Intervention

Device:
• Suprachoroidal Dissection Instrument (SDI)
The Suprachoroidal Dissection Instrument (SDI) is a manually operated, non-powered, re-usable ophthalmic surgical instrument. The SDI is designed to enter a surgically exposed Schlemm's canal and be advanced up to 90 degrees around the canal from the entry site.

Locations

Country	Name	City	State
United States	Glaucoma Associates of Texas	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
iScience Interventional Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Postoperative intraocular pressure, glaucoma medication usage, and visual acuity		12 months	Yes